Nang Kuang Pharmaceutical Co., Ltd.
TWSE:1752.TW
36.95 (TWD) • At close May 8, 2025
Overview | Financials
Numbers are in millions (except for per share data and ratios) TWD.
| 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue
| 2,199.861 | 2,150.228 | 1,940.487 | 1,780.098 | 1,754.827 | 1,762.259 | 1,538.527 | 1,503.72 | 1,549.708 | 1,520.328 | 1,276.782 | 1,012.922 | 952.138 | 813.122 | 652.827 | 670.027 |
| Cost of Revenue
| 1,452.068 | 1,394.665 | 1,245.585 | 1,185.631 | 1,158.07 | 1,139.954 | 1,039.012 | 987.375 | 974.001 | 971 | 867.27 | 716.402 | 624.121 | 561.826 | 449.262 | 432.706 |
| Gross Profit
| 747.793 | 755.563 | 694.902 | 594.467 | 596.757 | 622.305 | 499.515 | 516.345 | 575.707 | 549.328 | 409.512 | 296.52 | 328.017 | 251.296 | 203.565 | 237.321 |
| Gross Profit Ratio
| 0.34 | 0.351 | 0.358 | 0.334 | 0.34 | 0.353 | 0.325 | 0.343 | 0.371 | 0.361 | 0.321 | 0.293 | 0.345 | 0.309 | 0.312 | 0.354 |
| Reseach & Development Expenses
| 169.362 | 164.108 | 143.808 | 133.965 | 159.802 | 130.772 | 154.68 | 135.838 | 116.397 | 106.28 | 114.438 | 103.949 | 73.312 | 80.278 | 55.739 | 44.987 |
| General & Administrative Expenses
| 113.901 | 106.793 | 95.805 | 88.709 | 86.289 | 112.016 | 86.371 | 82.456 | 84.665 | 81.093 | 68.819 | 66.42 | 61.973 | 55.271 | 63.295 | 63.99 |
| Selling & Marketing Expenses
| 156.983 | 145.989 | 131.48 | 115.345 | 125.446 | 131.544 | 130.824 | 137.029 | 144.863 | 150.947 | 134.551 | 126.603 | 108.235 | 96.773 | 102.942 | 113.476 |
| SG&A
| 270.884 | 331.612 | 227.285 | 204.054 | 211.735 | 243.56 | 217.195 | 219.485 | 229.528 | 232.04 | 203.37 | 193.023 | 170.208 | 152.044 | 166.237 | 177.466 |
| Other Expenses
| 0 | 0 | 91.171 | -26.153 | 1.044 | 8.132 | -4.572 | 60.774 | 46.365 | 25.141 | -0.675 | 16.23 | 21.056 | 10.239 | 8.347 | 2.914 |
| Operating Expenses
| 440.246 | 495.652 | 371.093 | 338.019 | 371.537 | 374.332 | 371.875 | 355.323 | 345.925 | 338.32 | 317.808 | 296.972 | 243.52 | 232.322 | 221.976 | 222.453 |
| Operating Income
| 307.547 | 259.911 | 417.674 | 233.759 | 230.472 | 256.105 | 123.068 | 221.796 | 276.147 | 236.149 | 91.029 | 15.778 | 103.012 | 32.296 | -8.119 | 19.325 |
| Operating Income Ratio
| 0.14 | 0.121 | 0.215 | 0.131 | 0.131 | 0.145 | 0.08 | 0.147 | 0.178 | 0.155 | 0.071 | 0.016 | 0.108 | 0.04 | -0.012 | 0.029 |
| Total Other Income Expenses Net
| -4.343 | -46.233 | -7.048 | 1.001 | -6.864 | -5.281 | -5.331 | 56.643 | 40.423 | 15.62 | -9.108 | 6.154 | -9.456 | -8.151 | -0.825 | 2.73 |
| Income Before Tax
| 303.204 | 213.678 | 410.626 | 234.76 | 223.608 | 250.824 | 117.737 | 217.665 | 270.205 | 226.628 | 82.596 | 5.702 | 93.556 | 10.823 | -19.236 | 17.598 |
| Income Before Tax Ratio
| 0.138 | 0.099 | 0.212 | 0.132 | 0.127 | 0.142 | 0.077 | 0.145 | 0.174 | 0.149 | 0.065 | 0.006 | 0.098 | 0.013 | -0.029 | 0.026 |
| Income Tax Expense
| 59.796 | 15.269 | 58.627 | 38.649 | 40.21 | 33.384 | 16.505 | 31.848 | 44.706 | 27.641 | 15.314 | 13.52 | 13.182 | 4.661 | -8.651 | 5.662 |
| Net Income
| 243.408 | 198.409 | 351.999 | 196.111 | 183.398 | 217.44 | 101.232 | 185.817 | 225.499 | 198.987 | 67.282 | -7.818 | 80.374 | 6.162 | -10.585 | 11.936 |
| Net Income Ratio
| 0.111 | 0.092 | 0.181 | 0.11 | 0.105 | 0.123 | 0.066 | 0.124 | 0.146 | 0.131 | 0.053 | -0.008 | 0.084 | 0.008 | -0.016 | 0.018 |
| EPS
| 2.43 | 1.96 | 3.49 | 1.94 | 1.82 | 2.17 | 1 | 1.84 | 2.25 | 2.17 | 0.76 | -0.091 | 1.22 | 0.1 | -0.17 | 0.2 |
| EPS Diluted
| 2.43 | 1.96 | 3.48 | 1.94 | 1.81 | 2.17 | 1 | 1.84 | 2.23 | 1.98 | 0.68 | -0.091 | 1.13 | 0.1 | -0.17 | 0.2 |
| EBITDA
| 491.69 | 402.698 | 591.565 | 417.829 | 412.994 | 447.007 | 318.314 | 339.535 | 447.706 | 377.999 | 244.281 | 136.948 | 219.728 | 123.971 | 76.645 | 92.238 |
| EBITDA Ratio
| 0.224 | 0.187 | 0.305 | 0.235 | 0.235 | 0.254 | 0.207 | 0.226 | 0.289 | 0.249 | 0.191 | 0.135 | 0.231 | 0.152 | 0.117 | 0.138 |